In the News

Share
1662 News Items found
In the Clinic
Dr. Carol Aghajanian
For Advanced Endometrial Cancer, Chemotherapy Plus Immunotherapy Improves Outcomes
New research published in The New England Journal of Medicine finds adding the immunotherapy drug pembrolizumab (Keytruda®) to standard chemotherapy greatly improves outcomes in people with advanced endometrial cancer. The phase 3 study was overseen by MSK gynecologic medical oncologist Carol Aghajanian.
Finding
Michael Rosensweig with dog
Menin Inhibitors: Promising New Drug Treatment for Aggressive Leukemia
Results from the first-ever trial for a new class of leukemia drugs called menin inhibitors are encouraging.
A scientist pipetting in a lab
MSK Research Highlights, March 9, 2023
New research from MSK offers new proof-of-concept compounds against acute myeloid leukemia; reports results from a phase 1 clinical trial appraising two drugs against low- grade glioma; examines MSK’s first-in-the-nation program integrating herbal medicine into oncology care; and identifies how high-grade histologic patterns in lymph node metastases could better predict lung cancer outcomes.
MSK physician-scientists Michele Sadelain, Isabelle Riviere, and Jae Park
Testing CRISPR-Edited CAR T Cell Therapy in Lymphoma Clinical Trial
A groundbreaking clinical trial is testing CAR T cells created using CRISPR gene-editing technology.
SKI biomedical engineer Dr. Daniel Heller
Getting Drugs Across the Blood-Brain Barrier Using Nanoparticles
Learn how MSK researchers are investigating the use of nanoparticles to carry drugs across the blood-brain barrier.
Melanie Steele, MPH, Director of Patient Financial Engagement at PFS
Making Cancer Treatment More Affordable: MSK Nurses Ensuring Access to Care
Memorial Sloan Kettering Cancer Center (MSK) is committed not only to providing exceptional cancer care but also to ensuring access to care for everyone who needs it. Unfortunately, some patients — often those whose insurance plan offers a very narrow provider network or those who are underinsured — have trouble shouldering the significant financial burden that can come with a cancer diagnosis. MSK has a special team in place to make sure these patients can still get the care they deserve.
A scientist holds a box of frozen samples
MSK Research Highlights, February 23, 2023
New research from MSK offers a window into patients’ complex decision-making around adjuvant therapy, explores the promise of engineered CAR T cells, highlights the success of a summer research program to support groups underrepresented in science, and more.
Q&A
Dr. Sergio Giralt
Improving Treatment for Recurrent Multiple Myeloma With Ide-Cel CAR T Therapy
In this Q&A, MSK hematologic oncologist Sergio Giralt, MD, talks about a phase 3 trial of ide-cel CAR T therapy for people with recurrent multiple myeloma and what it may mean for people with this hard-to-treat blood cancer.
woman getting vaccine from doctor
HPV Vaccine Age Limit: You Might Not Be Too Old — What You Should Know
Learn from MSK experts what people over 26 should know about getting the HPV vaccine to protect themselves from several forms of cancer.
Tobias M. Hohl, MD, PhD
Tobias M. Hohl Elected a 2022 AAAS Fellow
Tobias M. Hohl, MD, PhD, Chief of the Infectious Diseases Service in the Department of Medicine, was elected a 2022 Fellow of the American Association for the Advancement of Science (AAAS), the world’s largest scientific society and publisher of the Science journals. This title is one of the most distinguished honors within the scientific community and is designed to recognize leaders for their notable contributions to science.